Replies to post #122512 on Biotech Values

[DewDiligence]

That’s what makes the factoid in #msg-64637084 even more surprising: one would think that the in-house drugs are being measured from an earlier stage, on average, than the in-licensed drugs, and hence they should have a higher failure rate.